Table 2 Adherence by TRIPOD item among obstetrical prediction model studies, n (%)

Title

1 Study presentation in title

16 (13.2)

5 (5.4)

1 (10.0)

2 (33.3)

8 (66.7)

Abstract

2 Summary of the study

7 (5.8)

2 (2.2)

3 (30.0)

0 (0.0)

2 (16.7)

Background and objectives

3a Key contents of background

114 (94.2)

87 (93.5)

9 (90.0)

6 (100.0)

12 (100.0)

3b objectives of model

119 (98.3)

91 (97.8)

10 (100.0)

6 (100.0)

12 (100.0)

 Source of data

4a Design/data source

119 (98.3)

91 (97.8)

10 (100.0)

6 (100.0)

12 (100.0)

4b Study dates

33 (27.3)

21 (22.6)

5 (50.0)

0 (0.0)

7 (58.3)

 Participants

5a Key elements of setting

97 (80.2)

71 (76.3)

9 (90.0)

6 (100.0)

11 (91.7)

5b Participant eligibility

115 (95.0)

88 (94.6)

9 (90.0)

6 (100.0)

4 (100.0)

5c Details of treatments

24/37 (64.9) ^a

16/26 (61.5) ^a

0/2 (0.00)

2/2 (100.0) ^a

6/7 (85.7) ^a

 Outcome

6a Outcome definition

96 (79.3)

75 (80.6)

8 (80.0)

3 (50.0)

10 (83.3)

6b Blind assessment of outcome

49 (40.5)

37 (39.8)

3 (30.0)

1 (16.7)

8 (66.7)

 Predictors

7a Predictor definition

82 (67.8)

61 (65.6)

8 (80.0)

4 (66.7)

83 (68.0)

7b Blind assessment

3 (2.5)

3 (3.2)

0 (0.0)

0 (0.0)

0 (0.0))

 Sample size

8 How to arrive at the size

18 (14.9)

12 (12.9)

0 (0.0)

1 (16.7)

5 (41.7)

 Missing data

9 Handling missing data

36 (29.8)

24 (25.8)

2 (20.0)

1 (16.7)

9 (75.0)

 Statistical analysis method

10a Predictor handling

15/111 (13.5) ^a

9 (9.7)

NA

0 (0.0)

6 (50.0)

10b Model-building procedures

5/111 (4.5) ^a

4 (4.3)

NA

0 (0.0)

1 (8.3)

10c Calculation for validation

23/28 (82.1) ^a

NA

9 (90.0)

2 (33.3)

12 (100.0)

10d Model performance

22/111 (19.8) ^a

15/87 (17.2) ^a

3/7 (42.9) ^a

0/5 (0.0) ^a

4 (33.3)

10e Model updating

7/11 (63.6) ^a

NA

1/4 (25.0) ^a

6 (100.0)

0 (0.0) ^a

 Risk groups

11 Details to create risk groups

18/41 (43.9) ^a

10/30 (33.3) ^a

3/3 (100.0)

NA

5/8 (62.5)

 Development vs. validation

12 Differences of validation from development

17/28 (60.7) ^a

NA

2 (20.0)

6 (100.0)

9 (75.0)

 Participants

13a Flow of participants through the study

10 (8.3)

7 (7.5)

1 (10.0)

0 (0.0)

2 (16.7)

13b Characteristics of participants

40 (33.1)

24 (25.8)

4 (40.0)

3 (50.0)

9 (75.0)

13c Comparison of validation with development

15/28 (53.6) ^a

NA

2 (20.0)

6(100.0)

7 (58.3)

 Model development

14a Numbers

104/111 (93.7) ^a

87 (93.5)

NA

6 (100.0)

11 (91.7)

14b Unadjusted association of each candidate predictor and outcome

60/94 (63.8) ^a

48/80 (60.0) ^a

NA

4/4 (100.0) ^a

8/10 (80.0) ^a

 Model specification

15a Present the full model

49/111 (44.1) ^a

40 (43.0)

NA

2 (33.3)

7 (58.3)

15b How to use the model

15/111 (13.5) ^a

8 (8.6)

NA

0 (0.0)

7 (58.3)

 Model performance

16 Performance measures

16/111 (14.4) ^a

9/87 (10.3) ^a

3/7 (42.9) ^a

0/5 (0.0) ^a

4 (33.3)

 Model updating

17 Results from any updating

1/2 (50.0) ^a

NA

1/2 (50.0) ^a

NA

0 (0.0)

 Limitations

18 Any limitations of the study

113 (93.4)

89 (95.7)

9 (90.0)

4 (66.7)

11 (91.7)

 Interpretations

19a Comparing results of validation with development

24/28 (85.7) ^a

NA

6 (60.0)

6 (100.0)

12 (100.0)

19b Overall interpretation of results

120 (99.2)

92 (98.9)

10 (100.0)

6 (100.0)

12 (100.0)

 Implications

20 Potential implication

75 (62.0)

59 (63.4)

4 (40.0)

2 (33.3)

10 (83.3)

 Supplementary information

21 Information about supplementary resources (Optional)

53 (43.8)

44 (47.3)

1 (10.0)

1 (16.7)

7 (58.3)

 Funding

22 Funding information

14 (11.6)

9 (9.7)

1 (10.0)

0 (0.0)

4 (33.3)